Skip to main content

Peer Review reports

From: Efficacy and safety of upadacitinib, a selective JAK-1 inhibitor in treatment of ankylosing spondylitis: a meta-analysis

Original Submission
18 Jul 2024 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
31 Aug 2024 Reviewed Reviewer Report - Helou Zhang
25 Sep 2024 Reviewed Reviewer Report
27 Oct 2024 Author responded Author comments - Zhiqing Zhang
Resubmission - Version 3
27 Oct 2024 Submitted Manuscript version 3
21 Nov 2024 Reviewed Reviewer Report - Helou Zhang
4 Dec 2024 Reviewed Reviewer Report
6 Dec 2024 Reviewed Reviewer Report
18 Dec 2024 Author responded Author comments - Zhiqing Zhang
Resubmission - Version 4
18 Dec 2024 Submitted Manuscript version 4
19 Dec 2024 Author responded Author comments - Zhiqing Zhang
Resubmission - Version 5
19 Dec 2024 Submitted Manuscript version 5
28 Dec 2024 Reviewed Reviewer Report
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
1 Feb 2025 Editorially accepted
18 Feb 2025 Article published 10.1186/s41927-025-00467-1

You can find further information about peer review here.

Back to article page